Table 1 Patient characteristics at baseline
Intervention group (n = 30) | Control group (n = 30) | ||||
|---|---|---|---|---|---|
n | % | n | % | ||
Age (years) | Mean (SD) | 61.3 (10.1) | 64.1 (10.9) | ||
Gender | Male | 14 | 46.7 | 19 | 63.3 |
Female | 16 | 53.3 | 11 | 36.7 | |
Karnofsky-index (median, range) | 80 (70–100) | 80 (70–100) | |||
Primary site | |||||
Lung cancer | 12 | 40.0 | 8 | 26.6 | |
Breast cancer | 5 | 16.7 | 6 | 20.1 | |
Prostate cancer | 5 | 16.7 | 9 | 30.1 | |
Melanoma | 1 | 3.3 | 1 | 3.3 | |
Renal cancer | 1 | 3.3 | 2 | 6.7 | |
Other | 6 | 20.1 | 4 | 13.4 | |
Localization metastases | |||||
Thoracic | 17 | 56.7 | 14 | 46.7 | |
Lumbar | 9 | 30.0 | 13 | 43.3 | |
Thoracic and lumbar | 2 | 6.7 | 2 | 6.7 | |
Sacrum | 2 | 6.7 | 1 | 3.3 | |
Number metastases | |||||
Mean (range) | 1.4 (2-4) | 1.7 (1-5) | |||
Solitary | 22 | 73.3 | 18 | 60.0 | |
Multiple | 8 | 26.7 | 12 | 40.0 | |
Type of metastases | |||||
Mixed | 2 | 6.7 | 2 | 6.7 | |
Osteoblastic | 9 | 30.0 | 10 | 33.3 | |
Osteolytic | 19 | 63.3 | 18 | 60.0 | |
Distant metastases at baseline | |||||
Visceral | 12 | 40.0 | 5 | 16.7 | |
Brain | 3 | 10.0 | 3 | 10.0 | |
Lung | 7 | 23.3 | 4 | 13.3 | |
Tissue | 8 | 26.7 | 6 | 20.0 | |
Hormonotherapy | 10 | 33.3 | 16 | 53.3 | |
Immunotherapy | 7 | 23.3 | 5 | 16.7 | |
Chemotherapy | 25 | 83.3 | 20 | 66.7 | |
Ataractics | 4 | 13.3 | 2 | 6.7 | |
NSAR | 19 | 63.3 | 23 | 76.7 | |
Opioids | 11 | 36.7 | 13 | 43.3 | |